ReviewMaterials today. Bio2025
Metabolism-based artificial organelles: From precise construction to smart theranostics.
Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Copper-Doped Prussian Blue Nanozymes With Hyaluronic Acid-Mediated Targeting Alleviate Oxidative Stress and Regulate Cholesterol Handling for Atherosclerosis Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cellular metabolic dysregulation is a core driver of major diseases, including cancer, neurodegenerative disorders, and cardiovascular conditions. However, conventional interventions such as small-molecule drugs and gene editing are hampered by off-target effects, delivery challenges, and a lack of spatiotemporal precision, resulting in a failure to effectively reengineer pathological metabolic networks. Artificial organelles, constructed via a "bottom-up" bioinspired approach, represent a paradigm shift from systemic intervention to "metabolic system reconstruction," offering a revolutionary strategy to precisely mimic, repair, or augment specific metabolic functions at the subcellular level. Here, we systematically review recent advances in metabolism-based artificial organelles, from their precise construction to smart theranostic applications. We first elaborate on the core construction strategies, including lipid and protein self-assembly, microfluidics, 3D bioprinting and biomembrane fusion for enabling dynamic interactions and content delivery, followed by a dissection of the design principles for modulating three metabolic pillars: (1) remodeling energy metabolism by mimicking mitochondrial function and regulating glycolysis; (2) controlling biosynthesis by emulating the endoplasmic reticulum (ER) and substance transport networks; and (3) reshaping redox homeostasis by mimicking peroxisomes through multienzyme cascades and intelligent responsive systems that precisely regulate signaling molecules such as reactive oxygen species (ROS). We link these functional designs to specific metabolic vulnerabilities in diseases and showcase applications in neurodegenerative disorders, cancer, cardiovascular diseases, and inflammatory conditions. Specific strategies include repairing damaged neurons through synergistic energy supplementation and antioxidation or inhibiting tumors via a combination of "starvation therapy" and pro-oxidative "gas therapy." Finally, we critically address the key challenges in biocompatibility, systemic complexity,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.